Journal article
Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis
Journal of Crohn's and colitis, v 19(10), jjaf181
10 Oct 2025
PMID: 41071055
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Prior studies showed worse outcomes in obese inflammatory bowel disease (IBD) patients, especially those related to hospitalizations, surgery and steroid-free remission. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated significant metabolic benefits for patients with type 2 diabetes mellitus (T2DM) and obesity. Hence, GLP1-RAs may improve clinical outcomes in patients with IBD, especially those with obesity. The objective was to systematically evaluate the impact of GLP1-RAs on clinical outcomes in patients with IBD.
A comprehensive literature search was performed using the databases PubMed, Embase, Web of Science, and Cochrane Library from inception to 15-03-2025. Studies reporting outcomes related to GLP1-RAs in patients with IBD were included. Primary outcomes included weight loss and various IBD-related co-endpoints such as hospitalizations, surgery, corticosteroid use, and advanced therapy initiation.
In total, 11 studies with 16,242 patients with IBD treated with GLP1-RAs were included. Weight loss was achieved using semaglutide (-9.6 kg, CI-95% -12.0; -7.2), liraglutide (-9.4 kg, CI-95% -13.0; -5.8) and tirzepatide (-11.8 kg, CI-95% -18.3; -5.4) after 3 months of follow-up. In meta-analyses, GLP1-RAs were associated with lower risk of surgery for effect sizes (logHR: 0.61 [95%-CI 0.44-0.84], I2 = 0%) and event frequencies (OR: 0.46 [95%-CI 0.32-0.67], I2 = 42%). Sensitivity analysis for BMI showed lower risk of hospitalizations and surgery in patients with obesity (BMI≥30).
Patients with IBD and obesity using GLP1-RAs were able to achieve significant weight loss and had lower risks of surgery and hospitalizations. Our findings require confirmation in prospective trials of GLP1-RAs in IBD.
Metrics
13 Record Views
Details
- Title
- Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis
- Creators
- Ahmed B Bayoumy (Corresponding Author) - Amsterdam University Medical CentersLindsay M Clarke - Brigham and Women's HospitalParakkal Deepak - Washington University in St. LouisAakash Desai - Allegheny Health NetworkPriya Sehgal - Thomas Jefferson University HospitalYuri Gorelik - Rambam Health Care CampusHaggai Bar-Yoseph - Rambam Health Care CampusMarie Villumsen - Center for Clinical Research and PreventionChris J J Mulder - Amsterdam University Medical CentersDirk J Stenvers - University of AmsterdamMaarten E Tushuizen - Leiden University Medical CenterNanne K H de Boer - Amsterdam University Medical Centers
- Publication Details
- Journal of Crohn's and colitis, v 19(10), jjaf181
- Publisher
- Oxford University Press
- Number of pages
- 16
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:001627685300001
- Scopus ID
- 2-s2.0-105023543572
- Other Identifier
- 991022135679004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Gastroenterology & Hepatology